TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission
26. April 2017 08:30 ET
|
TESARO, Inc.
VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimenUp to 50% of patients undergoing highly or moderately...
Tesaro Announces Participation in Two Investor Conferences
25. April 2017 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences....
TESARO to Announce First-Quarter 2017 Financial Results on May 9, 2017
25. April 2017 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its first-quarter 2017 financial results on Tuesday, May 9, 2017, after the close of the U.S. financial...
TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S.
19. April 2017 16:15 ET
|
TESARO, Inc.
ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancerZEJULA is the only PARP inhibitor that has demonstrated a clinically...
Tesaro Wins Awards for Clinical Development Team of the Year and Clinical Partnership of the Year
07. April 2017 08:30 ET
|
TESARO, Inc.
WALTHAM, Mass., April 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, has been recognized with two Clinical and Research Excellence (CARE)...
TESARO Announces Expanded Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast Cancer
27. März 2017 15:45 ET
|
TESARO, Inc.
Expanded niraparib ovarian cancer program intended to potentially transform the treatment of front-line ovarian cancerNew breast cancer clinical program for niraparib to address greatest area of unmet...
Tesaro Announces Presentation of Niraparib Phase 3 ENGOT-OV16/NOVA Trial Secondary Endpoint Results During SGO
13. März 2017 11:10 ET
|
TESARO, Inc.
NATIONAL HARBOR, Md., March 13, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of secondary endpoint results...
TESARO Announces Niraparib Data Presentations at the 2017 SGO Annual Meeting on Women’s Cancer
12. März 2017 08:38 ET
|
TESARO, Inc.
WALTHAM, Mass., March 12, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced two niraparib presentations at the 2017 Society for...
TESARO Announces Fourth-Quarter 2016 Operating Results
28. Februar 2017 16:05 ET
|
TESARO, Inc.
Niraparib NDA under review by FDA; pre-launch preparations for planned commercial launch well underwayExpanded access program (EAP) for niraparib open in U.S.; European EAP expected to open 1H...
TESARO Receives Positive CHMP Opinion for VARUBY®
27. Februar 2017 02:00 ET
|
TESARO, Inc.
WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for...